Central Nervous System Disease Market

Delivered January 12th, 2018. Contributors: krishnan U., Justus M., Ramadhani H. and

Part

of three

Part

CNS Global Market Size

The global market for the CNS diseases market in 2018 is $86.6 billion. According to a report from Grand View Research, the CNS diseases market size will reach USD 128.9 billion by 2025 based on an annual growth rate of 5.9% CAGR. 
market researchIn 2016, the CNS therapeutic market size was USD 77.2 billion, according to this market research report from Grand View Research. The same report projects a growth rate of 5.9% CAGR for the forecast period of 2016-2025. Based on these figures, I was able to estimate the market size for 2018 as $86.6 billion using this CAGR calculator. 

 Grand View Research reports that by 2025, the CNS therapeutic market will reach $128.9 billion. Increasing awareness of psychiatric disorders, expanding psychiatric disorders, and unhealthy lifestyle choices are driving the growth of diseases of the central nervous system, leading to growth in the market.

Also in my research, I learned that, over the next 9 years, the treatment of Parkinson’s and Alzheimer’s diseases will witness extensive growth, another driver of the market. In the mental health sector, major economies in the Asia Pacific region will witness growth.

 Some notable players in the pharmaceutical field for CNS related diseases are Pfizer, Inc.; Teva Pharmaceutical Industries Ltd.; Biogen, Inc.; Johnson & Johnson Services, Inc.; Eli Lilly and Company; and Novartis AG.
Conclusion:For the CNS diseases market, the projected market growth is from $77.2 billion in 2016 to $128.9 billion in 2025, a growth rate of 5.9% CAGR. The current market size for CNS disease market is $86.6 Billion.

Part

of three

Part

CNS Market Main Competitors

The four main competitors in the global CNS (central nervous system) disease treatment market based on majority share are Pfizer Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., and Novartis AG. They are active in the development of treatments for CNS diseases and have treatments such as somatrogon, fingolimod, Laquinimod, Aducanumab (Aβ mAb), and rivipansel in the pipeline for treatment of different CNS diseases. 

THE CNS THERAPEUTICS MARKET
The therapeutic market for CNS disease treatment has a compound annual growth rate of 5.9% and will reach $128.9 billion by the year 2025. The market growth is driven by a rise in the prevalence of mental diseases and the increasing awareness of psychiatric disorders. The major players in the industry based on majority share are Pfizer Inc., Biogen Inc., Teva Pharmaceutical Industries Ltd., and Novartis AG. Pfizer has a rare disease team that focuses on develop effective therapies for the patients affected by rare disorders. The Orphan Drug Act of 1983 defined the rare disorders as diseases affecting less than 200,000 people in the United States.  

The market size for the treatment of Parkinson's disease was $4.24 billion in the year 2017 and will reach $5.69 billion by 2022 due to its compound annual growth rate of 6.1%. Pfizer Inc. and Teva Pharmaceutical Industries Limited are global competitors in the treatment of overactive bladder whose market will grow at a compound annual growth rate of 2.9% to reach $4.19 billion by the year 2022. 

PFIZER INC.
The treatments in their pipeline for the treatment of CNS diseases include tafamidis meglumine, rivipansel, somatrogon, and domagrozumab. Tafamidis meglumine is transthyretin (TTR) dissociation inhibitor and is in the registration stage. Rivipansel is a pan-selectin antagonist and is in phase 3 of testing while somatrogon is a human growth hormone agonist and is in the third phase of testing. Domagrozumab is a myostatin inhibitor and is in the second phase of testing. Pfizer is also developing dopamine 1 activator, which is in the second phase, for the treatment of Parkinson's disease.

TEVA PHARMACEUTICAL INDUSTRIES LTD.
The company is focusing on a pipeline of novel treatments and new drugs aimed at treating CNS conditions. Azilect is in the registration stage for the treatment of Parkison's disease, and Austedo is in the third phase of testing for the treatment of Tourette syndrome. Other treatments in the second phase of testing for the treatment of Huntington disease are Pridopidine and Laquinimod. Laquinimod will also help in the treatment of multiple sclerosis. 

BIOGEN INC.
The company has various treatments in development for the treatment of CNS diseases. The treatments in the pipeline for the treatment of Alzheimer's disease include Aducanumab (Aβ mAb), E2609 (BACE1 inhibitor), BAN2401 (Aβ mAb), BIIB076, and BIIB092. Aducanumab (Aβ mAb) and E2609 are in the third stage of development, BAN2401 (Aβ mAb) is in the second phase, while BIIB076, and BIIB092 are in the first phase of development. The company also has BIIB054 (anti-α-synuclein) in the first phase of development for the treatment of Parkinson's disease. BIIB098 (monomethyl fumarate prodrug) is in the third phase of testing and Opicinumab (anti-LINGO) is in the second phase of testing for the treatment of multiple sclerosis.  

NOVARTIS AG.
The treatments in the pipeline for the treatment of Alzheimer's disease are amilomotide and CNP520, and they are both in the second phase of development. A treatment known as fingolimod is also in the registration phase and will be used for the treatment of pediatric multiple sclerosis. Norvatis is also developing a treatment known as Nilotinib (Tasigna®), which was successful in the first phase of treatment of Parkinson's disease but is yet to proceed to the second phase because of disagreements on how to run it. 

CONCLUSION
In conclusion, the four major competitors in the CNS (central nervous system) disease treatment market globally based on majority share are Pfizer Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., and Novartis AG. The companies also have various treatments such as rivipansel, somatrogon, fingolimod, Aducanumab (Aβ mAb), and Laquinimod in the pipeline for the treatment of different CNS diseases. 

Part

of three

Part

CNS Trends

The main trends affecting the evolution of needs by Central Nervous System (CNS) disease stakeholders are rising CNS disorders due to aging populations and lifestyle choices, increasing awareness of CNS disorders, technological innovations for early diagnosis, generic therapies taking center stage as patents expire and pharmaceuticals working to reverse recent declines in CNS therapy investments as a result of US Food and Drug Administration approval challenges. This brief provides an overview of trends in the CNS therapeutics sector followed by an in depth look at CNS drug approvals.
CNS Therapeutics market trendsFindings of research on the global CNS therapeutics market conducted by Global Industry Analysts indicate that increasing cases of psychiatric and neurodegenerative disorders are fueling the sector's growth, which could "reach US$145 billion by 2024." Acceptance of new treatment innovations as well as a rise in the number of old people and cases of Parkinson's and Alzheimer's disease are also driving growth. In addition, Global Industry Analysts predicts increasing developing country healthcare budgets will play a part in the global rise of CNS therapeutics. Finally, CNS therapeutics is likely to see a proliferation of generic therapies as branded drug patents expire.

A report published by Grand View Research similarly projects a compound annual growth rate of 5.9% for CNS therapeutics, taking the sector to US$128.9 billion by 2025 from US$77.2 billion in 2016. Factors driving this growth include more cases of mental illness and "awareness of psychiatric disorders," aging populations as well as increasing "lifestyle-associated CNS disorders." Grand View Research also expect a strong increase in the demand for Parkinson’s and Alzheimer’s treatments globally. 

Another key growth driver is "neurological imaging" innovations for "early diagnosis." Awareness campaigns by healthcare institutions such as the World Health Organization and American Association of Neurological Surgeons in partnership with leading pharmaceutical companies are fueling the take-up of early diagnosis.

The main CNS therapeutics pharmaceutical firms identified by Global View Research's report are Pfizer, Teva Pharmaceutical Industries, Biogen, Johnson & Johnson Services, Eli Lilly and Company, and Novartis AG.
CNS Drug ApprovalsCNS disorder treatments "are limited" because the number of CNS drugs being developed is "comparatively low." Research indicates that the US Federal Drug Administration (FDA) only approves 8.2% of potential CNS disorder medications which discourages pharmaceutical companies from investing in them. In addition, compared to other therapeutics, CNS drugs take much longer and cost more to introduce.

The FDA has strict development regulations for CNS drugs because they target "children, the elderly, disabled and mentally ill" who are classified as vulnerable. These regulations are often too taxing for pharmaceuticals to pursue especially when CNS disorders remain "poorly understood."

According to the Trends in Dealmaking, 2012-16 report published by Research and Markets, the FDA only made 12 CNS therapy approvals for that period, down from 19 for 2007-11. This compares to 50 new oncology therapy approvals for 2012-16, up from 24 for 2007-11. Research and Markets' report further established that CNS therapeutics was the "only major therapeutic area to see a decrease in approvals from the 2007-11 period to the 2012-16 period." As a result, there is "significant opportunity" for investment in new CNS therapeutics. 

To cope with the research and development challenges outlined above, CNS therapeutics research is trying to emulate oncology by adopting macro-management approaches in place of traditional micro-management approaches with more promising results. Data from the Halloran Consulting Group shows "significant increases in deal volume, size and stage of development since 2014."
ConclusionMore CNS disorders caused by aging populations and lifestyle choices, rising awareness of CNS disorders, technological innovations for early diagnosis, proliferation of generic therapies and pharmaceuticals changing their CNS therapy investment approaches to cope with strict FDA guidelines are the primary trends affecting the evolution of needs by CNS disease stakeholders. As such, there is huge investment potential in CNS therapeutics with the sector projected to grow to between US$128.9 billion and US$145 billion by 2025.